<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Vivosim Labs, Inc. — News on 6ix</title>
<link>https://6ix.com/company/vivosim-labs-inc</link>
<description>Latest news and press releases for Vivosim Labs, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/vivosim-labs-inc" rel="self" type="application/rss+xml" />
<item>
<title>VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-platform-predicts-gastrointestinal-toxicity-diarrhea-in-an-ai-model-trained-on-human-intestinal-model-results-without-animal-testing</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-platform-predicts-gastrointestinal-toxicity-diarrhea-in-an-ai-model-trained-on-human-intestinal-model-results-without-animal-testing</guid>
<pubDate>Tue, 28 Apr 2026 12:05:00 GMT</pubDate>
<description>VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy resultsSAN DIEGO, April 28, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the availability of an AI prediction tool leveraging its NAMkind™ intestinal models to accurately predict the potential of a given drug compound to cause diarrhea in patients. The tool int</description>
</item>
<item>
<title>VivoSim Announces Pricing of up to a $4 Million Public Offering</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-announces-pricing-of-up-to-a-dollar4-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-announces-pricing-of-up-to-a-dollar4-million-public-offering</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach</description>
</item>
<item>
<title>VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-releases-antibody-drug-conjugate-adc-data-showing-power-to-detect-adc-toxicity-and-guide-design-of-safer-adcs</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity</description>
</item>
<item>
<title>VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-appoints-arumugham-ragoo-raghunathan-as-vice-president-of-global-sales</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-appoints-arumugham-ragoo-raghunathan-as-vice-president-of-global-sales</guid>
<pubDate>Tue, 03 Mar 2026 13:05:00 GMT</pubDate>
<description>Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with biopharma innovators seeking human-relevant liver and GI toxicity solutionsSAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the appoi</description>
</item>
<item>
<title>VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-debut-antibody-drug-conjugate-130500090</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-debut-antibody-drug-conjugate-130500090</guid>
<pubDate>Wed, 11 Feb 2026 13:05:00 GMT</pubDate>
<description>Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effectsSAN DIEGO, Feb. 11, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it will attend the Society of Toxicology (“SOT”) meeting in San Diego, CA that takes place March 22-25 and present new data on it</description>
</item>
<item>
<title>NIO Inc. Provides January 2026 Delivery Update</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/nio-inc-provides-january-2026-delivery-update</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/nio-inc-provides-january-2026-delivery-update</guid>
<pubDate>Sun, 01 Feb 2026 08:00:00 GMT</pubDate>
<description>27,182 vehicles were delivered in January 2026, increasing by 96.1% year-over-yearCumulative deliveries reached 1,024,774 as of January 31, 2026 SHANGHAI, Feb. 01, 2026 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its January 2026 delivery results. The Company delivered 27,182 vehicles in January 2026, representing an increase of 96.1% year-over-year. The deliv</description>
</item>
<item>
<title>VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-expands-asia-pacific-access-210500337</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-expands-asia-pacific-access-210500337</guid>
<pubDate>Thu, 29 Jan 2026 21:05:00 GMT</pubDate>
<description>JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in</description>
</item>
<item>
<title>VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-labs-appoints-amar-sethi-130500732</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-labs-appoints-amar-sethi-130500732</guid>
<pubDate>Tue, 06 Jan 2026 13:05:00 GMT</pubDate>
<description>Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platformsSAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine, announces it has appointed Amar Sethi,</description>
</item>
<item>
<title>NIO Inc. Provides November 2025 Delivery Update</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/nio-inc-provides-november-2025-delivery-update</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/nio-inc-provides-november-2025-delivery-update</guid>
<pubDate>Mon, 01 Dec 2025 09:30:00 GMT</pubDate>
<description>36,275 vehicles were delivered in November 2025, increasing by 76.3% year-over-year277,893 vehicles were delivered year-to-date in 2025, increasing by 45.6% year-over-year Cumulative deliveries reached 949,457 as of November 30, 2025 SHANGHAI, Dec. 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its November 2025 delivery results. The Company delivered 36</description>
</item>
<item>
<title>NIO Inc. Provides September and Third Quarter 2025 Delivery Update</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/nio-inc-provides-september-and-third-quarter-2025-delivery-update</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/nio-inc-provides-september-and-third-quarter-2025-delivery-update</guid>
<pubDate>Wed, 01 Oct 2025 07:45:00 GMT</pubDate>
<description>Company Achieved New Record-High Monthly and Quarterly Deliveries 34,749 vehicles were delivered in September 2025, increasing by 64.1% year-over-year87,071 vehicles were delivered in the three months ended September 2025, increasing by 40.8% year-over-yearCumulative deliveries reached 872,785 as of September 30, 2025 SHANGHAI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicl</description>
</item>
<item>
<title>NIO Inc. Announces Pricing of US$1 Billion Equity Offering</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/nio-inc-announces-pricing-of-usdollar1-billion-equity-offering</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/nio-inc-announces-pricing-of-usdollar1-billion-equity-offering</guid>
<pubDate>Wed, 10 Sep 2025 13:16:00 GMT</pubDate>
<description>SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced the pricing of its US$1 billion offering (the “Equity Offering”) relating to a total of 181,818,190 Class A ordinary shares of the Company, which consists of an offering of American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company (the “ADS Offering”), a</description>
</item>
<item>
<title>NIO Inc. Announces Proposed Equity Offering</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/nio-inc-announces-proposed-equity-offering</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/nio-inc-announces-proposed-equity-offering</guid>
<pubDate>Wed, 10 Sep 2025 08:58:00 GMT</pubDate>
<description>SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced a proposed offering (the “Equity Offering”) relating to a total of up to 181,818,190 Class A ordinary shares of the Company, which consists of an offering of American depositary shares (“ADSs”), each representing one Class A ordinary share of the Company (the “ADS Offering”) and an offering o</description>
</item>
<item>
<title>NIO Inc. Achieved 31,305 Vehicle Deliveries in August 2025</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/nio-inc-achieved-31305-vehicle-deliveries-in-august-2025</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/nio-inc-achieved-31305-vehicle-deliveries-in-august-2025</guid>
<pubDate>Mon, 01 Sep 2025 09:30:00 GMT</pubDate>
<description>Company Achieved New Record-High Monthly Deliveries31,305 vehicles were delivered in August 2025, increasing by 55.2% year-over-year166,472 vehicles were delivered year-to-date in 2025, increasing by 30.0% year-over-year Cumulative deliveries reached 838,036 as of August 31, 2025 SHANGHAI, Sept. 01, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the global smart electric vehicle market, today announced its August 2</description>
</item>
<item>
<title>VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-labs-appoints-tony-lialin-120500194</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-labs-appoints-tony-lialin-120500194</guid>
<pubDate>Thu, 14 Aug 2025 12:05:00 GMT</pubDate>
<description>Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing marketSAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial</description>
</item>
<item>
<title>VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-namkind-intestine-wins-blue-120500540</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-namkind-intestine-wins-blue-120500540</guid>
<pubDate>Tue, 13 May 2025 12:05:00 GMT</pubDate>
<description>SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for infl</description>
</item>
<item>
<title>VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-presents-best-class-liver-120500211</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-presents-best-class-liver-120500211</guid>
<pubDate>Wed, 07 May 2025 12:05:00 GMT</pubDate>
<description>SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced today that its world-leading NAMkind™ platform for liver toxicology prediction, provided as a commercial service to pharma companies, was featured in an oral presentation at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025) showing best-in-class predictive power against a set of test liver compounds. VivoSim’s liver predictive power was shown to be 87.5% for a set of challen</description>
</item>
<item>
<title>VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-announces-emergence-stealth-mode-120500690</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-announces-emergence-stealth-mode-120500690</guid>
<pubDate>Thu, 24 Apr 2025 12:05:00 GMT</pubDate>
<description>SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA’s push to phase out animal models, announced on April</description>
</item>
<item>
<title>VivoSim to Carry Forward Organovo 3D Bioprinting</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/vivosim-to-carry-forward-organovo-3d-bioprinting</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/vivosim-to-carry-forward-organovo-3d-bioprinting</guid>
<pubDate>Wed, 23 Apr 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”) announced that it will carry forward its 3D bioprinting</description>
</item>
<item>
<title>Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/organovo-provides-update-on-cash-and-nasdaq-continued-listing-requirements</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/organovo-provides-update-on-cash-and-nasdaq-continued-listing-requirements</guid>
<pubDate>Wed, 02 Apr 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company</description>
</item>
<item>
<title>Organovo Provides Business Update</title>
<link>https://6ix.com/company/vivosim-labs-inc/news/organovo-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/vivosim-labs-inc/news/organovo-provides-business-update</guid>
<pubDate>Thu, 27 Mar 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company</description>
</item>
</channel>
</rss>